A clinical trial to study the effect of triple combination of Triglow cream containing Hydroquinone, Tretinoin and Fluocinolone acetonide in patients with facial melasma.
Phase 4
Completed
- Conditions
- Health Condition 1: null- Facial Melasma
- Registration Number
- CTRI/2011/091/000054
- Lead Sponsor
- Glenmark Pharmaceutical Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
?Subjects with facial Melasma and not used any topical treatments for Melasma for 2 weeks prior to enrollment in study.
?Subjects must be 18 and above.
?Subjects must provide written informed consent and comply to the protocol
Exclusion Criteria
?Subjects who had used any topical treatment for Melasma for 2 weeks prior to enrollment in study.
?Subjects under treatment for a dermatologic condition, which may interfere with the safe evaluation of the study combination (e.g. eczema, psoriasis, severe sun-damage, dermatitis)
?Hypersensitivity to any ingredients of Triglow
?Subjects who have undergone any surgical treatment of the face.
?Subjects with a diagnosis of skin cancer in the areas to be treated.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in the Area of facialMelasma. ? Improvement in the luminance of facial MelasmaTimepoint: 4 weeks and 8 weeks
- Secondary Outcome Measures
Name Time Method ILTimepoint: NI